Specific killing of CCR9 high-expressing acute T lymphocytic leukemia cells by CCL25 fused with PE38 toxin

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1254-1260

  Hu, Yi ^a   Zhang, Li ^a   Wu, Ranran ^a   Han, Rongfei ^a   Jia, Yanhan ^a   Jiang, Zhengming ^a   Cheng, Mengxin ^a   Gan, Jing ^a   Tao, Xiang ^a   Zhang, Qiuping ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Acute T lymphocytic leukemia; CCL25; CCR9; CCR9+ tumor; MOLT4; PE38

Indexed keywords

CCL25 PSEUDOMONAS EXOTOXIN 38; CHEMOKINE RECEPTOR CCR9; IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN 38; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL KILLING; CELL SURFACE; CHEMOTAXIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA;

ADP RIBOSE TRANSFERASES; ANIMALS; APOPTOSIS; BACTERIAL TOXINS; CELLS, CULTURED; CHEMOKINES, CC; DRUG EVALUATION, PRECLINICAL; EXOTOXINS; FEMALE; HUMANS; MICE; MICE, SCID; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, CCR; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051472624     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.015     Document Type: Article

References (26)

1. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12(2):121-127.
2. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
3. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121(3):335-348.
4. Hartmann T.N., Burger J.A., Glodek A., Fujii N., Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005, 24(27):4462-4471.
5. Mashino K., Sadanaga N., Yamaguchi H., Tanaka F., Ohta M., Shibuta K., et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 2002, 62(10):2937-2941.
6. Uehara S., Song K., Farber J.M., Love P.E. Characterization of CCR9 expression and CCL25/thymus-expressed chemokine responsiveness during T cell development: CD3 (high) CD69+ thymocytes and gamma delta TCR+ thymocytes preferentially respond to CCL25. J Immunol 2002, 168(1):134-142.
7. Johnson E.L., Singh R., Singh S., Johnson-Holiday C.M., Grizzle W.E., Partridge E.E., et al. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol 2010, 8:62.
8. Qiuping Z., Jei X., Youxin J., Wei J., Chun L., Jin W., et al. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation. Cancer Res 2004, 64(20):7579-7587.
9. Qiuping Z., Qun L., Chunsong H., Xiaolian Z., Baojun H., Mingzhen Y., et al. Selectively increased expression and functions of chemokine receptor CCR9 on CD4+ T cells from patients with T-cell lineage acute lymphocytic leukemia. Cancer Res 2003, 63(19):6469-6477.
10. Kunkel E.J., Campbell J.J., Haraldsen G., Pan J., Boisvert J., Roberts A.I., et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000, 192(5):761-768.
11. Nagakubo D., Jin Z., Hieshima K., Nakayama T., Shirakawa A.K., Tanaka Y., et al. Expression of CCR9 in HTLV-1+ T cells and ATL cells expressing Tax. Int J Cancer 2007, 120(7):1591-1597.
12. Pastan I., Hassan R., FitzGerald D.J., Kreitman R.J. Immunotoxin treatment of cancer. Annu Rev Med 2007, 58:221-237.
13. Becker S.E. The disease with hope: hairy cell leukemia. Clin J Oncol Nurs 2007, 11(5):731-735.
14. Onda M., Wang Q.C., Guo H.F., Cheung N.K., Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9 (Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004, 64(4):1419-1424.
15. Zhang L., Yu B., Hu M., Wang Z., Liu D., Tong X., et al. Role of Rho-ROCK signaling in MOLT4 cells metastasis induced by CCL25. Leuk Res 2011, 35(1):103-109.
16. Baatar D., Olkhanud P., Newton D., Sumitomo K., Biragyn A. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol 2007, 179(3):1996-2004.
17. Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I. B3 (Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 1991, 88(19):8616-8620.
18. Walters M.J., Wang Y., Lai N., Baumgart T., Zhao B.N., Dairaghi D.J., et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010, 335(1):61-69.
19. Yadav V.R., Sung B., Prasad S., Kannappan R., Cho S.G., Liu M., et al. Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med 2010, 88(12):1243-1253.
20. Ishida T., Iida S., Akatsuka Y., Ishii T., Miyazaki M., Komatsu H., et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 2004, 10(22):7529-7539.
21. Chen W., Li H., Jia Y., Lv M., Li M., Feng P., et al. In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2007, 28(1):30-40.
22. Crittenden M., Gough M., Chester J., Kottke T., Thompson J., Ruchatz A., et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 2003, 63(12):3173-3180.
23. Chen S.Y., Yang A.G., Chen J.D., Kute T., King C.R., Collier J., et al. Potent antitumour activity of a new class of tumour-specific killer cells. Nature 1997, 385(6611):78-80.
24. Borroni E.M., Mantovani A., Locati M., Bonecchi R. Chemokine receptors intracellular trafficking. Pharmacol Ther 2010, 127(1):1-8.
25. Keppler-Hafkemeyer A., Kreitman R.J., Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer 2000, 87(1):86-94.
26. Hu C.C., Ke Y.Q., Sun X.L., Jiang X.D., Xu R.X., Lv J. Human mesenchymal stem cells-like cells as cellular vehicles for delivery of immunotoxin in vitro. Biotechnol Lett 2009, 31(2):181-189.